A new Stanford blood test detects cancer and tissue damage by analyzing rare RNA fragments in the blood. Stanford Medicine ...

With the American Association for Cancer Research’s annual conference now underway, oncology researchers can expect ...

It's the third most-common cancer in the USA, and the leading cause of cancer deaths—and doesn't only affect whom you might ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced HER2-mutant non-small cell lung cancer – particularly those with specific HER2 ...

On Saturday, May 3, more than 150 firefighters from five departments across the Atlanta area will join the American Lung Association to raise awareness and critical funds for people living with lung ...

Zongertinib shows promise for treating HER2-mutant non–small cell lung cancer (NSCLC), with significant activity against brain metastases and low interstitial lung disease risk, explains John Heymach, ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced ...

Zongertinib, an oral therapy shown to have strong responses in patients previously treated for HER2 -mutated non–small cell ...

Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...

Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck cancer, metastatic breast cancer and lung cancer.

A groundbreaking new urine test could soon help spot the early warning signs of lung cancer long before symptoms appear.

Stanford Medicine researchers have developed a blood test capable of detecting cancers, the ways cancer resists treatments ...